Qi-Jing Wang

1.4k total citations
26 papers, 1.1k citations indexed

About

Qi-Jing Wang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Qi-Jing Wang has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 18 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Qi-Jing Wang's work include Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Qi-Jing Wang is often cited by papers focused on Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Qi-Jing Wang collaborates with scholars based in China, United States and Hong Kong. Qi-Jing Wang's co-authors include Jian‐Chuan Xia, De-Sheng Weng, Jing-Jing Zhao, Yong-Qiang Li, Qiu-Zhong Pan, Jia He, Ke Pan, Shan-Shan Jiang, Shi-Ping Chen and Li-Xi Huang and has published in prestigious journals such as PLoS ONE, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Qi-Jing Wang

26 papers receiving 1.1k citations

Peers

Qi-Jing Wang

ONCOL

IMMUN

PFM

HEPAT

Yong-Qiang Li China

Carl C. Schimanski Germany

Li-Xi Huang China

Shi-Ping Chen China

Ilaria Marech Italy

Yagai Yang United States

Pierre Combe France

Suzanne Fioravanti United States

Vito Vanella Italy

Tong Ding China

Yong-Qiang Li China

Qi-Jing Wang

677 ×1.0

ONCOL

670 ×1.0

IMMUN

271 ×0.8

153 ×1.0

PFM

140 ×1.0

HEPAT

Citations per year, relative to Qi-Jing Wang Qi-Jing Wang (= 1×) peers Yong-Qiang Li

Countries citing papers authored by Qi-Jing Wang

Since Specialization

Citations

This map shows the geographic impact of Qi-Jing Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qi-Jing Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qi-Jing Wang more than expected).

Fields of papers citing papers by Qi-Jing Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qi-Jing Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qi-Jing Wang. The network helps show where Qi-Jing Wang may publish in the future.

Co-authorship network of co-authors of Qi-Jing Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Qi-Jing Wang. A scholar is included among the top collaborators of Qi-Jing Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qi-Jing Wang. Qi-Jing Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pan, Qiu-Zhong, Qing Liu, Jing-Jing Zhao, et al.. (2020). CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunology Immunotherapy. 69(5). 825–834. 15 indexed citations

Chen, Chang-Long, Qiu-Zhong Pan, De-Sheng Weng, et al.. (2017). Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. OncoImmunology. 7(4). e1417721–e1417721. 42 indexed citations

Chen, Chang-Long, Qiu-Zhong Pan, Jing-Jing Zhao, et al.. (2016). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology. 5(7). e1176653–e1176653. 51 indexed citations

Pan, Qiu-Zhong, Qi-Jing Wang, Ke Pan, et al.. (2015). A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. Scientific Reports. 5(1). 9202–9202. 23 indexed citations

Zhang, Xiaofei, Jie Chao, Qiu-Zhong Pan, et al.. (2015). Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget. 6(38). 40920–40933. 28 indexed citations

Pan, Ke, Yong-Qiang Li, Jing-Jing Zhao, et al.. (2014). Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. Clinical Cancer Research. 20(11). 3003–3011. 77 indexed citations

Zhao, Jing-Jing, Qiu-Zhong Pan, Ke Pan, et al.. (2014). Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells. Scientific Reports. 4(1). 5177–5177. 93 indexed citations

Yan, Zheng, Wei Wang, Ke Pan, et al.. (2014). Reduced Expression of Uroplakin 1A Is Associated with the Poor Prognosis of Gastric Adenocarcinoma Patients. PLoS ONE. 9(4). e93073–e93073. 14 indexed citations

Pan, Qiu-Zhong, Ke Pan, Qi-Jing Wang, et al.. (2014). Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. Stem Cells. 33(2). 354–366. 56 indexed citations

10.

Zhao, Jing-Jing, Chun-yu Huang, Qi-Jing Wang, et al.. (2013). Decreased Expression of the FOXO3a Gene Is Associated with Poor Prognosis in Primary Gastric Adenocarcinoma Patients. PLoS ONE. 8(10). e78158–e78158. 44 indexed citations

11.

Zhang, Fei, Yong-Qiang Li, Haixia Zheng, et al.. (2013). Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies. Chinese Journal of Cancer. 32(12). 661–666. 3 indexed citations

12.

Pan, Ke, Yong-Qiang Li, Li Xu, et al.. (2013). The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Annals of Surgical Oncology. 20(13). 4305–4311. 68 indexed citations

13.

Zhao, Jing-Jing, Ke Pan, Qi-Jing Wang, et al.. (2013). Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. Chinese Journal of Cancer. 32(10). 553–60. 9 indexed citations

14.

Chen, Yi-bing, Ke Pan, Wei Wang, et al.. (2012). Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer. PLoS ONE. 7(7). e40364–e40364. 91 indexed citations

15.

Xia, Jian‐Chuan, Ke Pan, Wei Wang, et al.. (2011). Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients. International Journal of Biological Sciences. 7(1). 53–60. 90 indexed citations

16.

Pan, Ke, Min-Shan Chen, Qi-Jing Wang, et al.. (2010). Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biology & Therapy. 10(4). 368–375. 34 indexed citations

17.

Wang, Qi-Jing, Hui Wang, Ke Pan, et al.. (2010). Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chinese Journal of Cancer. 29(7). 641–648. 31 indexed citations

18.

Zhang, Lan-Jun, et al.. (2009). Dendritic cell-tumor cell fusion vaccine prevents growth of subcutaneous transplanted esophageal carcinomas. Chinese Journal of Cancer. 28(10). 1067–1071. 4 indexed citations

19.

Weng, De-Sheng, Jun Zhou, Ming Zhao, et al.. (2008). Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas. Journal of Immunotherapy. 31(1). 63–71. 127 indexed citations

20.

Xia, Jian‐Chuan, et al.. (2007). [Antitumor efficacy of fusion cells from esophageal carcinoma cells and dendritic cells as a vaccine in vitro].. PubMed. 26(2). 137–41. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact